News
Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...
2don MSN
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year ...
COMMENT: We need to have a grown up conversation about racism, writes Ava Vidal – and I believe people are missing what the ...
Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...
Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.
Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...
The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.
Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback